Currently out of the existing stock ratings of Judah Frommer, 154 are a BUY (67.25%), 70 are a HOLD (30.57%), 5 are a SELL (2.18%).

Judah Frommer

Work Performance Price Targets & Ratings Chart

Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 71.22% that have a potential upside of 42.42% achieved within 306 days. Previously, Judah Frommer worked at CREDIT SUISSE.

Judah Frommer’s has documented 453 price targets and ratings displayed on 47 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.

Most recent stock forecast was given on ABVX, Abivax SA American Depositary Shares at 02-Jun-2026.

Wall Street Analyst Judah Frommer

Analyst best performing recommendations are on ACLX (ARCELLX).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.

Average potential price target upside

of $45 on INBX (INHIBRX ).
of $34.56 (191.38%) on QURE (UNIQURE NV).
of $29.31 (58.45%) on IKNA (IKENA ONCOLOGY).

DLTR Dollar Tree FIVE Five Below JSPR Jasper Therapeutics KR Kroger Company OLLI Ollie's Bargain Outlet Hldg SYY Sysco USFD US Foods Holding Corp SFM Sprouts Farmers Market LLC ATAI ATAI Life Sciences BV CRTX Cortexyme EFTR Effector Therapeutics ESPR Esperion Therapeutics FLXN Flexion Therapeutics FULC Fulcrum Therapeutics INBX Inhibrx PEAR Pear Therapeutics PTCT PTC Therapeutics ABOS Acumen Pharmaceuticals RNA Avidity Biosciences DG Dollar General IKNA Ikena Oncology PFGC Performance Food Group Co SRPT Sarepta Therapeutics STOK Stoke Therapeutics BJ BJs Wholesale Club Holdings AKLI Akili CADL Candel Therapeutics INSM Insmed QURE Uniqure NV GLPG Galapagos NV ADR ACLX Arcellx FDMT 4D Molecular Therapeutics NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares APLS Apellis Pharmaceuticals BPMC Blueprint Medicines Corp CLDX Celldex Therapeutics RGNX Regenxbio ARQT Arcutis Biotherapeutics TRVI Trevi Therapeutics KYMR Kymera Therapeutics ABVX Abivax SA American Depositary Shares ACI Albertsons Companies BLTE Belite Bio ADR COST Costco Wholesale Corp PROK ProKidney Corp. SFS Smart & Final Stores VTYX Ventyx Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Kate Mcshane (GOLDMAN SACHS)